First Patient Dosed in Phase 2 Trial of Oral Treatment to Ease Inflammation in Parkinson’s

First Patient Dosed in Phase 2 Trial of Oral Treatment to Ease Inflammation in Parkinson’s
Alkahest announced the dosing of a first patient in the Phase 2 trial for its Parkinson’s therapy AKST4290, an oral tablet aiming to ease the inflammation that can aggravate disease symptoms. The efficacy and safety trial, called AKST4290-211 or TEAL (2019-001657-42), will measure AKST4290’s benefits in motor function and activities relevant to daily life in treated patients relative to those given a placebo, ... read more
Source: Parkinson’s News TodayPublished on 2020-02-06By Forest Ray, PhD